Norges Bank Bio Atla, Inc. Transaction History

Norges Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.37 - $3.92 $668,821 - $1.91 Million	488,191 New	488,191 $668,000
Q4 2023 Feb 09, 2024	BUY	$1.27 - $3.18 $620,002 - $1.55 Million	488,191 New	488,191 $1.2 Million
Q3 2023 Nov 13, 2024	BUY	$1.7 - $3.07 $829,924 - $1.5 Million	488,191 New	488,191 $829,000
Q1 2022 May 12, 2023	BUY	$4.38 - $18.78 $1.1 Million - $4.72 Million	251,200 New	251,200 $1.26 Million
Q1 2021 May 07, 2021	SELL	$32.41 - $70.91 $324,099 - $709,100	-10,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$31.02 - $35.16 $310,200 - $351,599	10,000 New	10,000 $340,000

17.4M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $16.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.